295 related articles for article (PubMed ID: 35757327)
1. Clinical Manifestations, Monitoring, and Prognosis: A Review of Cardiotoxicity After Antitumor Strategy.
Huang W; Xu R; Zhou B; Lin C; Guo Y; Xu H; Guo X
Front Cardiovasc Med; 2022; 9():912329. PubMed ID: 35757327
[TBL] [Abstract][Full Text] [Related]
2. Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer: a Delphi study.
Gavila J; Seguí MÁ; Calvo L; López T; Alonso JJ; Farto M; Sánchez-de la Rosa R
Clin Transl Oncol; 2017 Jan; 19(1):91-104. PubMed ID: 27101413
[TBL] [Abstract][Full Text] [Related]
3. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention.
Henriksen PA
Heart; 2018 Jun; 104(12):971-977. PubMed ID: 29217634
[TBL] [Abstract][Full Text] [Related]
4. Cardiac imaging techniques for the assessment of immune checkpoint inhibitor-induced cardiotoxicity and their potential clinical applications.
Li Y; Liu PJ; Zhang ZL; Wang YN
Am J Cancer Res; 2022; 12(8):3548-3560. PubMed ID: 36119829
[TBL] [Abstract][Full Text] [Related]
5. A Patent Review on Cardiotoxicity of Anticancerous Drugs.
Bhadana R; Rani V
Cardiovasc Hematol Agents Med Chem; 2023 Jan; ():. PubMed ID: 36683367
[TBL] [Abstract][Full Text] [Related]
6. Cardiotoxicities associated with immune checkpoint inhibitors.
Yang S; Asnani A
Curr Probl Cancer; 2018 Jul; 42(4):422-432. PubMed ID: 30173878
[TBL] [Abstract][Full Text] [Related]
7. Cardiotoxicity from neoadjuvant targeted treatment for breast cancer prior to surgery.
Liu Y; Zheng L; Cai X; Zhang X; Ye Y
Front Cardiovasc Med; 2023; 10():1078135. PubMed ID: 36910540
[TBL] [Abstract][Full Text] [Related]
8. Immune Checkpoint Inhibitors and Cardiac Toxicity in Patients Treated for Non-Small Lung Cancer: A Review.
Sławiński G; Wrona A; Dąbrowska-Kugacka A; Raczak G; Lewicka E
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 33003425
[TBL] [Abstract][Full Text] [Related]
9. Heart Failure in Relation to Anthracyclines and Other Chemotherapies.
Agunbiade TA; Zaghlol RY; Barac A
Methodist Debakey Cardiovasc J; 2019; 15(4):243-249. PubMed ID: 31988684
[TBL] [Abstract][Full Text] [Related]
10. Novel approaches to the prediction, diagnosis and treatment of cardiac late effects in survivors of childhood cancer: a multi-centre observational study.
Skitch A; Mital S; Mertens L; Liu P; Kantor P; Grosse-Wortmann L; Manlhiot C; Greenberg M; Nathan PC
BMC Cancer; 2017 Aug; 17(1):519. PubMed ID: 28774277
[TBL] [Abstract][Full Text] [Related]
11. Anthracycline-Induced Cardiotoxicity: Causes, Mechanisms, and Prevention.
Bhagat A; Kleinerman ES
Adv Exp Med Biol; 2020; 1257():181-192. PubMed ID: 32483740
[TBL] [Abstract][Full Text] [Related]
12. Cardiotoxicity in cancer immune-checkpoint therapy: Mechanisms, clinical evidence, and management strategies.
Sun JY; Qu Q; Lou YX; Hua Y; Sun GZ; Sun W; Kong XQ
Int J Cardiol; 2021 Dec; 344():170-178. PubMed ID: 34563597
[TBL] [Abstract][Full Text] [Related]
13. Prevention of Trastuzumab and Anthracycline-induced Cardiotoxicity Using Angiotensin-converting Enzyme Inhibitors or β-blockers in Older Adults With Breast Cancer.
Wittayanukorn S; Qian J; Westrick SC; Billor N; Johnson B; Hansen RA
Am J Clin Oncol; 2018 Sep; 41(9):909-918. PubMed ID: 28537988
[TBL] [Abstract][Full Text] [Related]
14. Benefits of antihypertensive medications for anthracycline- and trastuzumab-induced cardiotoxicity in patients with breast cancer: Insights from recent clinical trials.
Rygiel K
Indian J Pharmacol; 2016; 48(5):490-497. PubMed ID: 27721532
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies.
Dempsey N; Rosenthal A; Dabas N; Kropotova Y; Lippman M; Bishopric NH
Breast Cancer Res Treat; 2021 Jul; 188(1):21-36. PubMed ID: 34115243
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms and potential interventions associated with the cardiotoxicity of ErbB2-targeted drugs: Insights from in vitro, in vivo, and clinical studies in breast cancer patients.
Leemasawat K; Phrommintikul A; Chattipakorn SC; Chattipakorn N
Cell Mol Life Sci; 2020 Apr; 77(8):1571-1589. PubMed ID: 31650186
[TBL] [Abstract][Full Text] [Related]
17. Anthracycline-related cardiotoxicity in childhood cancer survivors.
Lipshultz SE; Karnik R; Sambatakos P; Franco VI; Ross SW; Miller TL
Curr Opin Cardiol; 2014 Jan; 29(1):103-12. PubMed ID: 24284979
[TBL] [Abstract][Full Text] [Related]
18. Challenges and solutions in management of cardiotoxicity induced by checkpoint inhibitors.
Mladosievičová B; Országhová Z; Jablonická M; Rečková M; Chovanec M; Mego M
Klin Onkol; 2020; 33(5):350-355. PubMed ID: 33108879
[TBL] [Abstract][Full Text] [Related]
19. Assessment and Management of Cardiotoxicity in Hematologic Malignancies.
Bojan A; Torok-Vistai T; Parvu A
Dis Markers; 2021; 2021():6616265. PubMed ID: 33613788
[TBL] [Abstract][Full Text] [Related]
20. Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management.
Zhou YW; Zhu YJ; Wang MN; Xie Y; Chen CY; Zhang T; Xia F; Ding ZY; Liu JY
Front Pharmacol; 2019; 10():1350. PubMed ID: 31849640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
